Formulations and API manufacturer Alembic Pharmaceuticals reported a 15 percent on-year (YoY) growth in in consolidated net profit for the June quarter at Rs 154 crore, driven by strong growth in the US generics business that saw a 13 percent increase in sales.
The consolidated revenue from operations for the June quarter rose by 10 percent to Rs.1,711 crore. EBITDA for the quarter rose 20% to Rs 288 crore, while the EBITDA margin improved 200 basis points to 17 percent.
Sales growth in the US generics market were strong, rising by 13 percent to Rs 523 crore, attributed to new launches and increased market share. The company filed 6 ANDA approvals received during the quarter, 223 Cumulative ANDA approvals. Ex-US International generics grew by 21% to Rs. 328 crore for the quarter.
The India branded business grew by 5 percent to Rs 599 crore led by good momentum in specialty therapies with Gynaecology, Cardiology, Anti-Diabetic, Ophthalmology and Animal healthcare segments demonstrating healthy growth. -infective and Cough & Cold segments grew in line with represented market performance, with robust operational execution. The company launched 3 new products during the quarter
Alembic Pharma spent 8% of its sales as R&D expenditure targeting complex injectables.
"We began FY26 on a strong note, delivering revenue growth across all businesses. The growth was driven by a 21% increase in RoW markets, reflecting our strategic expansion and disciplined execution across geographies," said Pranav Amin, Managing Director of Alembic Pharma
"Despite ongoing pricing pressure, our US business grew by 13%, supported by volume gains. As we
ramp up utilization of our new manufacturing facilities and continue to drive cost
optimization initiatives, we expect to benefit from improved operating leverage," Amin added.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
